PRIMARY OBJECTIVES:
I. Determine whether infertility and/or biomarkers of spermatogenesis and steroidogenesis differ in male osteosarcoma survivors treated with cisplatin with or without ifosfamide compared to male controls without a history of cancer.
II. Evaluate whether cisplatin with or without ifosfamide for the treatment of osteosarcoma alters sperm deoxyribonucleic acid (DNA) methylation.
EXPLORATORY OBJECTIVES:
I. Evaluate the role of genetic susceptibility in the development of impairments in spermatogenesis or steroidogenesis with contemporary regimens for the treatment of osteosarcoma.
OUTLINE:
Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.
Inclusion Criteria:
* Received upfront therapies for osteosarcoma, which included cisplatin, (with or without other agents)
* Patient must have completed cancer treatment \>= 2 years prior to study enrollment
* Osteosarcoma survivors without a systemically treated relapse or subsequent malignancy
* Note: History of relapse or second malignancy is permitted if treated with local therapy only (e.g. surgery, radiation)
* Able to speak, read and write in English, French or Spanish
* All patients and/or their parents or legal guardians must sign a written informed consent
* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
